Your browser doesn't support javascript.
loading
Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Muranushi, Hiroyuki; Kanda, Junya; Kobayashi, Masayuki; Maeda, Takeshi; Kitano, Toshiyuki; Tsuji, Masaaki; Ueda, Yasunori; Ishikawa, Takayuki; Nohgawa, Masaharu; Watanabe, Mitsumasa; Imada, Kazunori; Moriguchi, Toshinori; Itoh, Mitsuru; Ohno, Hitoshi; Yonezawa, Akihito; Hirata, Hirokazu; Arima, Nobuyoshi; Asagoe, Kohsuke; Anzai, Naoyuki; Nagata, Kayoko; Yasuno, Shinji; Kuwabara, Yoshihiro; Kitao, Hiromi; Kim, Ihhwa; Kawagishi, Kiyomi; Ueshima, Kenji; Tominari, Shinjiro; Nakayama, Takeo; Yamashita, Kouhei; Takaori-Kondo, Akifumi.
Afiliação
  • Muranushi H; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kanda J; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kobayashi M; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Maeda T; Department of Hematology, Japan Baptist Hospital, Kyoto, Japan.
  • Kitano T; Department of Haematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Tsuji M; Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan.
  • Ueda Y; Department of Hematology and Immunology, Otsu Red Cross Hospital, Otsu, Japan.
  • Ishikawa T; Department of Haematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Nohgawa M; Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan.
  • Watanabe M; Department of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.
  • Imada K; Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
  • Moriguchi T; Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Itoh M; Department of Internal Medicine, Kyoto-Katsura Hospital, Kyoto, Japan.
  • Ohno H; Department of Hematology, Kyoto City Hospital, Kyoto, Japan.
  • Yonezawa A; Department of Hematology, Tenri Hospital, Tenri, Japan.
  • Hirata H; Department of Hematology, Kokura Memorial Hospital, Kitakyushu, Japan.
  • Arima N; Department of Hematology, Kansai Electric Power Hospital, Osaka, Japan.
  • Asagoe K; Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan.
  • Anzai N; Department of Hematology and Oncology, Shiga General Hospital, Moriyama, Japan.
  • Nagata K; Department of Hematology and Oncology, Takatsuki Red Cross Hospital, Takatsuki, Japan.
  • Yasuno S; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kuwabara Y; Clinical Research Support Center, The Jikei University School of Medicine, Tokyo, Japan.
  • Kitao H; Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
  • Kim I; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
  • Kawagishi K; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
  • Ueshima K; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
  • Tominari S; Center for Accessing Early Promising Treatment, Kyoto University Hospital, Kyoto, Japan.
  • Nakayama T; Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
  • Yamashita K; Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
  • Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hematology ; 27(1): 239-248, 2022 Dec.
Article em En | MEDLINE | ID: mdl-35152852
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco / Quimioterapia de Indução / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco / Quimioterapia de Indução / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article